{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Staphylococcus+%28S.%29+Aureus+Infection",
    "query": {
      "condition": "Staphylococcus (S.) Aureus Infection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Staphylococcus+%28S.%29+Aureus+Infection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T07:34:44.847Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00911430",
      "title": "Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Staphylococcal Aureus Infection",
        "Recurrent Staphylococcal Infection",
        "Invasive Staphylococcal Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2009-05-28",
      "completion_date": "2014-09-17",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911430"
    },
    {
      "nct_id": "NCT00814151",
      "title": "MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bacteremia",
        "Staphylococcal Infection",
        "Sepsis",
        "Infection"
      ],
      "interventions": [
        {
          "name": "MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "MicroPhage, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 712,
      "start_date": "2008-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2008-12-24",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 3,
      "location_summary": "Evanston, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00814151"
    },
    {
      "nct_id": "NCT01104662",
      "title": "Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Complicated Skin and Skin Structure Infections",
        "S. Aureus Bacteremia",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Semi-Synthetic Penicillin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2010-04-19",
      "completion_date": "2012-06-12",
      "has_results": true,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 10,
      "location_summary": "Azusa, California • Los Angeles, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01104662"
    },
    {
      "nct_id": "NCT02940626",
      "title": "Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia, Ventilator-associated",
        "Pneumonia, Staphylococcal"
      ],
      "interventions": [
        {
          "name": "ASN100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arsanis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2016-11",
      "completion_date": "2018-09-28",
      "has_results": true,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Sacramento, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02940626"
    },
    {
      "nct_id": "NCT05184764",
      "title": "Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bacteremia",
        "Staphylococcus Aureus",
        "Staphylococcus Aureus Bacteremia",
        "Bacteremia Staph",
        "Bacteremia Due to Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "AP-SA02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Armata Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2022-04-26",
      "completion_date": "2025-01-14",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184764"
    },
    {
      "nct_id": "NCT06719219",
      "title": "A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcus (S.) Aureus Infection"
      ],
      "interventions": [
        {
          "name": "LTB-SA7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "LimmaTech Biologics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 129,
      "start_date": "2025-01-07",
      "completion_date": "2026-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06719219"
    },
    {
      "nct_id": "NCT00638157",
      "title": "Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infective Endocarditis"
      ],
      "interventions": [
        {
          "name": "daptomycin",
          "type": "DRUG"
        },
        {
          "name": "daptomycin and gentamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2009-02-13",
      "completion_date": "2011-11-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00638157"
    },
    {
      "nct_id": "NCT06805994",
      "title": "Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcal Aureus Infection",
        "Microbial Colonization",
        "Pediatric Infection",
        "S. Aureus Colonization",
        "Microbial Transplant"
      ],
      "interventions": [
        {
          "name": "Nasal Microbiota Transplant (NMT)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "0 Years to 60 Years"
      },
      "enrollment_count": 175,
      "start_date": "2025-08-27",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805994"
    },
    {
      "nct_id": "NCT05137119",
      "title": "Staphylococcus Aureus Network Adaptive Platform Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Penicillin",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Effectiveness of early switch to oral antibiotics",
          "type": "OTHER"
        },
        {
          "name": "Whole body FDG PET/CT Imaging",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "University of Melbourne",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8000,
      "start_date": "2022-02-16",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05137119"
    },
    {
      "nct_id": "NCT03163446",
      "title": "Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia",
        "Staphylococcus Aureus Endocarditis"
      ],
      "interventions": [
        {
          "name": "CF-301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ContraFect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2017-05-23",
      "completion_date": "2019-03-07",
      "has_results": true,
      "last_update_posted_date": "2021-10-08",
      "last_synced_at": "2026-06-11T07:34:44.847Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03163446"
    }
  ]
}